… In our study, the response rate for second-line erlotinib was 5.6%. A similar result was … and
erlotinib. However, there are still some patients getting benefits from second-line erlotinib after …

… A cost-effectiveness analysis was conducted which compares costs and effectiveness in
patients who received second-line erlotinib with those in patients who received docetaxel. …

… Thirty-two patients (65.3%) of the original 49 patients received second-line treatment, which
in … the percentage of patients who received second-line treatment among patients with EGFR …

… activity of metformin combined with erlotinib as second-line therapy in patients with stage IV
non–… II dose of metformin in combination with erlotinib. Secondary end points are the study of …

… Patients continued to receive erlotinib or placebo until progression or unacceptable toxicity
or death, and all patients in the placebo group were offered second-line erlotinib at the time …

… In patients with advanced NSCLC, 2nd/3rd-line erlotinib … safety of 1st line erlotinib in patients
with advanced NSCLC. … –2, NSCLC patients have been enrolled to receive erlotinib 150 mg/…

… On disease progression, patients in the gemcitabine plus cisplatin or … -line sequential
administration of erlotinib with chemotherapy has demonstrated promising results in patients with …

… second-line chemotherapies between erlotinib plus bevacizumab and panitumumab, and
erlotinib … The goal of our study was to explore optimal second-line treatment option for patients …

… This hypothesis needs to be tested in prospective randomized clinical trials of second- or
first-line therapy in patients with EGFR profiling to expand our insight regarding the role of …

… (OS) with maintenance erlotinib versus second-line erlotinib. Secondary objectives of the …
rate (DCR) between the study arms (erlotinib vs. placebo) during the blinded maintenance …